The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes

Journal of Virology

Volumn 89, Issue 1, 2015, Pages 120-128

  Weiskopf, Daniela ^a   Angelo, Michael A ^a   Bangs, Derek J ^a   Sidney, John ^a   Paul, Sinu ^a   Peters, Bjoern ^a   de Silva, Aruna D ^a,e   Lindow, Janet C ^b   Diehl, Sean A ^b   Whitehead, Stephen ^c   Durbin, Anna ^d   Kirkpatrick, Beth ^b   Sette, Alessandro ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e Genetech Research Institute   (Sri Lanka)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; EPITOPE; GAMMA INTERFERON; LIVE VACCINE; PROTEOME; VIRUS PROTEIN; VIRUS ANTIGEN;

ADULT; AGED; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENGUE; DRUG DOSAGE FORM COMPARISON; DRUG RESPONSE; DRUG TARGETING; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC CONSERVATION; HLA MATCHING; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOLOGICAL MEMORY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; INFECTION PREVENTION; INNATE IMMUNITY; MALE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN PROTEIN INTERACTION; VACCINATION; ADOLESCENT; DENGUE VIRUS; IMMUNOLOGY; MIDDLE AGED; NATIONAL HEALTH ORGANIZATION; SECRETION (PROCESS); UNITED STATES; YOUNG ADULT;

DENGUE VIRUS;

ADOLESCENT; ADULT; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; DENGUE VACCINES; DENGUE VIRUS; ENZYME-LINKED IMMUNOSPOT ASSAY; EPITOPES; FEMALE; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; NATIONAL INSTITUTES OF HEALTH (U.S.); UNITED STATES; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 84919431456     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02129-14     Document Type: Article

References (28)

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504-507. http://dx.doi.org/10.1038/nature12060.
2. Stahl HC, Butenschoen VM, Tran HT, Gozzer E, Skewes R, Mahendradhata Y, Runge-Ranzinger S, Kroeger A, Farlow A. 2013. Cost of dengue outbreaks: literature review and country case studies. BMC Public Health 13:1048. http://dx.doi.org/10.1186/1471-2458-13-1048.
3. Sabin AB. 1952. Research on dengue during World War II. Am J Trop Med Hyg 1:30-50.
4. Zellweger RM, Prestwood TR, Shresta S. 2010. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7:128-139. http://dx.doi.org/10.1016/j.chom.2010.01.004.
5. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, Sawasdivorn S, Duangchinda T, Dong T, Rowland-Jones S, Yenchitsomanus PT, McMichael A, Malasit P, Screaton G. 2003. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 9:921-927. http://dx.doi.org/10.1038/nm887.
6. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, Johnson S, Diamond MS, Beatty PR, Harris E. 2010. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6:e1000790. http://dx.doi.org/10.1371/journal.ppat.1000790.
7. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. 2012. Protective efficacy of the recombinant, liveattenuated, CYDtetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380:1559-1567. http://dx.doi.org/10.1016/S0140-6736(12)61428-7.
8. Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS. 2013. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis 207:957-965. http://dx.doi.org/10.1093/infdis/jis936.
9. + T cells. Proc Natl Acad Sci USA 110:E2046-E2053. http://dx.doi.org/10.1073/pnas.1305227110.
10. Lindow JC, Durbin AP, Whitehead SS, Pierce KK, Carmolli MP, Kirkpatrick BD. 2013. Vaccination of volunteers with low-dose, liveattenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles. Vaccine 31:3347-3352. http://dx.doi.org/10.1016/j.vaccine.2013.05.075.
11. Sette A, Sidney J. 1999. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and-B polymorphism. Immunogenetics 50:201-212. http://dx.doi.org/10.1007/s002510050594.
12. Kim Y, Ponomarenko J, Zhu Z, Tamang D, Wang P, Greenbaum J, Lundegaard C, Sette A, Lund O, Bourne PE, Nielsen M, Peters B. 2012. Immune epitope database analysis resource. Nucleic Acids Res 40:W525-W530. http://dx.doi.org/10.1093/nar/gks438.
13. Bui HH, Sidney J, Li W, Fusseder N, Sette A. 2007. Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinformatics 8:361. http://dx.doi.org/10.1186/1471-2105-8-361.
14. + T cell response. J Immunol 183:7919-7930. http://dx.doi.org/10.4049/jimmunol.0803903.
15. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A, CYD14 Study Group. 2014. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384:1358-1365. http://dx.doi.org/10.1016/S0140-6736(14)61060-6.
16. Madden DR. 1995. The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol 13:587-622. http://dx.doi.org/10.1146/annurev.iy.13.040195.003103.
17. van Kasteren SI, Overkleeft H, Ovaa H, Neefjes J. 2014. Chemical biology of antigen presentation by MHC molecules. Curr Opin Immunol 26:21-31. http://dx.doi.org/10.1016/j.coi.2013.10.005.
18. Neefjes J, Jongsma ML, Paul P, Bakke O. 2011. Towards a systems understanding ofMHCclass I andMHCclass II antigen presentation. Nat Rev Immunol 11:823-836. http://dx.doi.org/10.1038/nri3084.
19. Lindow JC, Borochoff-Porte N, Durbin AP, Whitehead SS, Fimlaid KA, Bunn JY, Kirkpatrick BD. 2012. Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans. PLoS Negl Trop Dis 6:e1742. http://dx.doi.org/10.1371/journal.pntd.0001742.
20. Weiskopf D, Angelo MA, Sidney J, Peters B, Shresta S, Sette A. 2014. Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection. J Virol 88:11383-11394. http://dx.doi.org/10.1128/JVI.01108-14.
21. Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, Malasit P, Mongkolsapaya J, Screaton G. 2010. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci USA 107:16922-16927. http://dx.doi.org/10.1073/pnas.1010867107.
22. + T lymphocytes in dengue virus infection. J Virol 87:2693-2706. http://dx.doi.org/10.1128/JVI.02675-12.
23. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. 2011. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29:7229-7241. http://dx.doi.org/10.1016/j.vaccine.2011.06.094.
24. Gordon A, Kuan G, Mercado JC, Gresh L, Aviles W, Balmaseda A, Harris E. 2013. The Nicaraguan pediatric dengue cohort study: incidence of inapparent and symptomatic dengue virus infections, 2004-2010. PLoS Negl Trop Dis 7:e2462. http://dx.doi.org/10.1371/journal.pntd.0002462.
25. Wikramaratna PS, Simmons CP, Gupta S, Recker M. 2010. The effects of tertiary and quaternary infections on the epidemiology of dengue. PLoS One 5:e12347. http://dx.doi.org/10.1371/journal.pone.0012347.
26. + T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses. Proc Natl Acad Sci USA 107:12599-12604. http://dx.doi.org/10.1073/pnas.1007270107.
27. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, Bean T, Barclay W, Deeks JJ, Lalvani A. 2013. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 19:1305-1312. http://dx.doi.org/10.1038/nm.3350.
28. Holmes EC, Twiddy SS. 2003. The origin, emergence and evolutionary genetics of dengue virus. Infect Genet Evol 3:19-28. http://dx.doi.org/10.1016/S1567-1348(03)00004-2.